Alternative chemotherapy regimen for patients with Hodgkin lymphoma

HD 21

Coordinating investigator

Dr. med.
Alden
Moccia
Istituto Oncologico della Svizzera Italiana (IOSI)
+41 91 811 47 64

In this trial, we investigate an alternative chemotherapy regimen (a combination of active substances for chemotherapy) for patients with Hodgkin lymphoma (tumor of the lymphatic system). We undertake this trial because while the current standard therapy offers a promising prognosis, it may also cause serious side effects. Therefore, we aim at finding a chemotherapy regimen that has the same efficacy, but with fewer or less serious side effects.

Currently, the standard chemotherapy for patients who have advanced Hodgkin lymphoma and are younger than 60 consists of six series of the BEACOPP regimen. BEACOPP identifies a combination of active substances used in the chemotherapy, in this case bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone. In this trial, we compare this regimen with the BrECADD regimen (brentuximab vedotin, etoposide, cyclophosphamide, adriamycin, dacarbazine, dexamethasone). Brentuximab vedotin is an antibody drug conjugate which tracks tumor cells and directs the cytostatic drug (a substance that constrains cell growth) to the tumor cells. This substance has shown a high efficacy with comparably few or less serious side effects in patients with recurrent Hodgkin lymphoma.  

Patients who suffer from an advanced Hodgkin lymphoma in the stage IIB or IV can participate in this trial.

All trials